Literature DB >> 35088096

Multimodal imaging of a patient with RAB39B mutation.

Laurane Mackels1, Martin Moïse2, Frédérique Depierreux3,4.   

Abstract

Mutations in RAB39B gene have been linked to intellectual deficiency associated with parkinsonism, also referred as to Waisman syndrome. As it appears to be a very rare cause of Parkinson Disease (PD), with only few cases described in the literature, the typical clinical and radiological features are yet to be determined. In this article, we report and illustrate multimodal brain imaging by computed tomography, magnetic resonance imaging, transcranial ultrasound (US), dopamine transporter single photon emission computed tomography and [18F]-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) in a 37-year-old man with PD features and mild mental retardation harboring a new RAB39B mutation. We then propose a comparison with data previously published regarding neuroimaging in this condition and present a summary of previous imaging reports. If our patient's results partly support previously described radiological features, they also highlight potential new characteristics of this rare syndrome. To the best of our knowledge, [18F]FDG-PET and transcranial US have never been reported before in this condition. This is therefore the first multimodal brain imaging description of a patient presenting RAB39B mutation.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Multimodal imaging; Parkinsonism; RAB39B; Waisman syndrome

Mesh:

Substances:

Year:  2022        PMID: 35088096     DOI: 10.1007/s00234-021-02882-w

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  5 in total

1.  In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage.

Authors:  D Berg
Journal:  J Neural Transm (Vienna)       Date:  2006-05-18       Impact factor: 3.575

2.  Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology.

Authors:  Gabrielle R Wilson; Joe C H Sim; Catriona McLean; Maila Giannandrea; Charles A Galea; Jessica R Riseley; Sarah E M Stephenson; Elizabeth Fitzpatrick; Stefan A Haas; Kate Pope; Kirk J Hogan; Ronald G Gregg; Catherine J Bromhead; David S Wargowski; Christopher H Lawrence; Paul A James; Andrew Churchyard; Yujing Gao; Dean G Phelan; Greta Gillies; Nicholas Salce; Lynn Stanford; Ashley P L Marsh; Maria L Mignogna; Susan J Hayflick; Richard J Leventer; Martin B Delatycki; George D Mellick; Vera M Kalscheuer; Patrizia D'Adamo; Melanie Bahlo; David J Amor; Paul J Lockhart
Journal:  Am J Hum Genet       Date:  2014-11-26       Impact factor: 11.025

3.  Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.

Authors:  Maila Giannandrea; Veronica Bianchi; Maria Lidia Mignogna; Alessandra Sirri; Salvatore Carrabino; Errico D'Elia; Matteo Vecellio; Silvia Russo; Francesca Cogliati; Lidia Larizza; Hans-Hilger Ropers; Andreas Tzschach; Vera Kalscheuer; Barbara Oehl-Jaschkowitz; Cindy Skinner; Charles E Schwartz; Jozef Gecz; Hilde Van Esch; Martine Raynaud; Jamel Chelly; Arjan P M de Brouwer; Daniela Toniolo; Patrizia D'Adamo
Journal:  Am J Hum Genet       Date:  2010-02-12       Impact factor: 11.025

4.  A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.

Authors:  Chang-He Shi; Shu-Yu Zhang; Zhi-Hua Yang; Jing Yang; Dan-Dan Shang; Cheng-Yuan Mao; Hao Liu; Hai-Man Hou; Meng-Meng Shi; Jun Wu; Yu-Ming Xu
Journal:  Mov Disord       Date:  2016-12       Impact factor: 10.338

5.  Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Nadya Pyatigorskaya; Clara B Sanz-Morère; Rahul Gaurav; Emma Biondetti; Romain Valabregue; Mathieu Santin; Lydia Yahia-Cherif; Stéphane Lehéricy
Journal:  Front Neurol       Date:  2020-05-28       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.